This study was conducted to characterize the metabolism and pharmacokinetic properties of NEO 212 in preclinical models. NEO 212, a conjugate of Temozolomide (TMZ) and Perillyl Alcohol (POH), has been shown to provide a method of providing chemotherapeutic treatment of brain-based-glioblastomas than the current TMZ-only therapy courses alone. In the study, NeOnc Technologies used mass […]

A new study conducted by NeOnc into the efficacy of its NEO 100 formulation to safely deliver therapeutics to the brain through the Blood-Brain Barrier was concluded in August 2020. This study was done to specifically study not only the ability to permeate the BBB but also the impact such migration would have on the […]

NeOnc Technologies Holdings conducted a study of its NEO100 Perillyl Alcohol (POH) formulation to determine its in vitro Blood-Brain Barrier (BBB) permeability using transepithelial/transendothelial electrical resistance (TEER) and antibody diffusion assays. Ultrasound-guided intracardiac administration of NEO100, followed by intravenous application of Evan’s blue, methotrexate, checkpoint-inhibitory antibodies, or CAR T-cells was conducted on mouse models. The […]

A new study into the effectiveness of NEO212, a conjugate formulation of Temozolomide (TMZ) and Perillyl Alcohol (POH) designed for intranasal delivery, to enhance the ability of (TMZ) to slow or stop the formation of Glioblastoma Tumors suggests additional benefits over TMZ treatment alone. For those with Glioblastoma (GB) brain cancer, the survival prognosis is […]